Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapacitabine in Elderly AML and MDS
NCT00590187Phase 2Completed
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Dec 2007
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sapacitabine in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (9 arms), sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoint: Overall Survival at 12 months. Started Dec 2007; status: completed.
02
Drugs
sapacitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT00590187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590187.